Here we demonstrate that targeting TOPK expression or kinase activity results in suppression of FLT3 expression and inhibition of CEBPA phosphorylation leading to enhanced myeloid differentiation and remarkable in vitro and in vivo anti-leukemia activity, particularly in FLT3-ITD AML. The gene discussed is PBK; the disease is leukemia.